Triaziquone

Triaziquone

SCHEMBL2216690

CCNN.O=C1C=C(N2CC2)C(=O)C(N2CC2)=C1N1CC1

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.39
HTT P42858 2/20 0.39
TP53 P04637 1/20 0.39
STAT3 P40763 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
DNMT1 P26358 1/20 0.38
NSD2 O96028 3/20 0.34
TTR P02766 1/20 0.34
APAF1 O14727 2/20 0.32
TDP2 O95551 2/20 0.32
HKDC1 Q2TB90 2/20 0.32
KMT2A Q03164 2/20 0.30
MEN1 O00255 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
GALK1 P51570 1/20 0.30
BLM P54132 1/20 0.30
ATM Q13315 1/20 0.30
NOD2 Q9HC29 1/20 0.30
ATG4B Q9Y4P1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Triaziquone SCHEMBL22118274 0.88 MAPT (0.40) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL33439 0.88 HTT (0.42) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL21358774 0.86 MAPT (0.43) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL149876 0.86 MAPT (0.46) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL11350903 0.84 HTT (0.42) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL5606305 0.84 HTT (0.42) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL7117809 0.84 MAPT (0.44) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL8303 0.84 DNMT1 (0.48) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL4612122 0.83 DNMT1 (0.41) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL6387848 0.83 MAPT (0.41) MAPTHTTTP53STAT3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11072629-B2 Reprogramming of cellular adhesion THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-07-27 US disclosed
US-20170305955-A1 Reprogramming of Cellular Adhesion UNITED STATES GOVERNMENT 2017-10-26 US disclosed
US-9650407-B2 Reprogramming of cellular adhesion THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-05-16 US disclosed
US-20140294782-A1 Reprogramming of Cellular Adhesion US ARMY, SECRETARY OF THE ARMY 2014-10-02 US disclosed
EP-2773327-A1 REPROGRAMMING OF CELLULAR ADHESION The Regents of The University of California (US) 2014-09-10 EP disclosed
WO-2013067203-A1 REPROGRAMMING OF CELLULAR ADHESION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-05-10 WO disclosed
US-20110177156-A1 Sterol-Modified Amphiphilic Lipids THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2011-07-21 US disclosed
EP-2219587-A1 STEROL-MODIFIED AMPHIPHILIC LIPIDS The Regents of the University of California (US) 2010-08-25 EP disclosed
WO-2009064696-A1 STEROL-MODIFIED AMPHIPHILIC LIPIDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110177156-A1 Sterol-Modified Amphiphilic Lipids SREBF1, SREBF2, SGMS1 MAPT 2307/4885HTT 2662/4885TP53 768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.